{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:52:22Z","timestamp":1794556342893,"version":"4.9.1"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We have identified a t(8;9)(p21-23;p23-24) in seven male patients (mean age 50, range 32-74) with diverse hematologic malignancies and clinical outcomes: atypical chronic myeloid leukemia\/chronic eosinophilic leukemia (n = 5), secondary acute myeloid leukemia (n = 1), and pre-B-cell acute lymphoblastic leukemia (n = 1). Initial fluorescence in situ hybridization studies of one patient indicated that the nonreceptor tyrosine kinase Janus-activated kinase 2 (JAK2) at 9p24 was disrupted. Rapid amplification of cDNA ends-PCR identified the 8p22 partner gene as human autoantigen pericentriolar material (PCM1), a gene encoding a large centrosomal protein with multiple coiled-coil domains. Reverse transcription-PCR and fluorescence in situ hybridization confirmed the fusion in this case and also identified PCM1\u2013JAK2 in the six other t(8;9) patients. The breakpoints were variable in both genes, but in all cases the chimeric mRNA is predicted to encode a protein that retains several of the predicted coiled-coil domains from PCM1 and the entire tyrosine kinase domain of JAK2. Reciprocal JAK2\u2013PCM1 mRNA was not detected in any patient. We conclude that human autoantigen pericentriolar material (PCM1)\u2013JAK2 is a novel, recurrent fusion gene in hematologic malignancies. Patients with PCM1\u2013JAK2 disease are attractive candidates for targeted signal transduction therapy.<\/jats:p>","DOI":"10.1158\/0008-5472.can-04-4263","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T21:52:59Z","timestamp":1126821179000},"page":"2662-2667","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":231,"title":["The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses <i>PCM1<\/i> to <i>JAK2<\/i>"],"prefix":"10.1158","volume":"65","author":[{"given":"Andreas","family":"Reiter","sequence":"first","affiliation":[{"name":"1III. Medizinische Universita\u0308tsklinik, Fakulta\u0308t fu\u0308r Klinische Medizin Mannheim der Universita\u0308t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Walz","sequence":"additional","affiliation":[{"name":"1III. Medizinische Universita\u0308tsklinik, Fakulta\u0308t fu\u0308r Klinische Medizin Mannheim der Universita\u0308t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Watmore","sequence":"additional","affiliation":[{"name":"2North Trent Cytogenetics Service, Sheffield Children's Hospital, Sheffield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schoch","sequence":"additional","affiliation":[{"name":"3Labor fu\u0308r spezielle Leuka\u0308miediagnostik and Medizinische Klinik III, Klinikum Gro\u03b2hadern, Ludwig-Maximilians-Universita\u0308t, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Blau","sequence":"additional","affiliation":[{"name":"4Ha\u0308matologisch-onkologische Schwerpunktpraxis, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[{"name":"5Medizinische Hochschule Hannover, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Berger","sequence":"additional","affiliation":[{"name":"1III. Medizinische Universita\u0308tsklinik, Fakulta\u0308t fu\u0308r Klinische Medizin Mannheim der Universita\u0308t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Telford","sequence":"additional","affiliation":[{"name":"6Oncology Cytogenetics Service, Christie Hospital, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilani","family":"Aruliah","sequence":"additional","affiliation":[{"name":"7Cytogenetics Laboratory, Mayday University Hospital, Croydon, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Yin","sequence":"additional","affiliation":[{"name":"8University Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vanstraelen","sequence":"additional","affiliation":[{"name":"9Department of Haematology and Oncology, Virga Jesse Hospital, Hasselt, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen F.","family":"Barker","sequence":"additional","affiliation":[{"name":"10Department of Haematology, Rotherham General Hospital, Rotherham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[{"name":"10Department of Haematology, Rotherham General Hospital, Rotherham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"O'Driscoll","sequence":"additional","affiliation":[{"name":"11Department of Haematology, Worthing Hospital, Worthing, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Benedetti","sequence":"additional","affiliation":[{"name":"12Centro Trapianto Midollo Osseo, Azienda Ospedaliera di Verona, Verona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Rudolph","sequence":"additional","affiliation":[{"name":"5Medizinische Hochschule Hannover, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Jochem","family":"Kolb","sequence":"additional","affiliation":[{"name":"3Labor fu\u0308r spezielle Leuka\u0308miediagnostik and Medizinische Klinik III, Klinikum Gro\u03b2hadern, Ludwig-Maximilians-Universita\u0308t, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"1III. Medizinische Universita\u0308tsklinik, Fakulta\u0308t fu\u0308r Klinische Medizin Mannheim der Universita\u0308t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru\u0308diger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"1III. Medizinische Universita\u0308tsklinik, Fakulta\u0308t fu\u0308r Klinische Medizin Mannheim der Universita\u0308t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chase","sequence":"additional","affiliation":[{"name":"13Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom; and"},{"name":"14Human Genetics Division, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.P.","family":"Cross","sequence":"additional","affiliation":[{"name":"13Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom; and"},{"name":"14Human Genetics Division, University of Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2005,4,1]]},"reference":[{"key":"2022061621035889100_B1","doi-asserted-by":"crossref","unstructured":"Goldman JM, Melo JV. Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment. N Engl J Med\u20082003; 349: 1451\u201364.","DOI":"10.1056\/NEJMra020777"},{"key":"2022061621035889100_B2","doi-asserted-by":"crossref","unstructured":"Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor \u03b2 to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell\u20081994; 77: 307\u201316.","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"2022061621035889100_B3","doi-asserted-by":"crossref","unstructured":"Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia\/lymphoma syndrome. Nat Genet\u20081998; 18: 84\u20137.","DOI":"10.1038\/ng0198-84"},{"key":"2022061621035889100_B4","doi-asserted-by":"crossref","unstructured":"Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood\u20081998; 92: 1735\u201342.","DOI":"10.1182\/blood.V92.5.1735.417k11_1735_1742"},{"key":"2022061621035889100_B5","doi-asserted-by":"crossref","unstructured":"Popovici C, Zhang B, Gregoire MJ, et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood\u20081999; 93: 1381\u20139.","DOI":"10.1182\/blood.V93.4.1381"},{"key":"2022061621035889100_B6","doi-asserted-by":"crossref","unstructured":"Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood\u20082000; 95: 1788\u201396.","DOI":"10.1182\/blood.V95.5.1788.005k15_1788_1796"},{"key":"2022061621035889100_B7","doi-asserted-by":"crossref","unstructured":"Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol\u20082002; 107: 101\u20137.","DOI":"10.1159\/000046639"},{"key":"2022061621035889100_B8","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Hochhaus A, Bolufer P, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet\u20082002; 11: 1391\u20137.","DOI":"10.1093\/hmg\/11.12.1391"},{"key":"2022061621035889100_B9","doi-asserted-by":"crossref","unstructured":"Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31\u201335: role of the platelet-derived growth factor receptor \u03b2. Acta Haematol\u20082002; 107: 113\u201322.","DOI":"10.1159\/000046641"},{"key":"2022061621035889100_B10","doi-asserted-by":"crossref","unstructured":"Cross NCP, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia\u20082002; 16: 1207\u201312.","DOI":"10.1038\/sj.leu.2402556"},{"key":"2022061621035889100_B11","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med\u20082003; 348: 1201\u201314.","DOI":"10.1056\/NEJMoa025217"},{"key":"2022061621035889100_B12","doi-asserted-by":"crossref","unstructured":"Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor \u03b2. N Engl J Med\u20082002; 347: 481\u20137.","DOI":"10.1056\/NEJMoa020150"},{"key":"2022061621035889100_B13","doi-asserted-by":"crossref","unstructured":"Stewart K, Carstairs KC, Dube ID, Keating A. Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. Am J Hematol\u20081990; 34: 59\u201363.","DOI":"10.1002\/ajh.2830340113"},{"key":"2022061621035889100_B14","doi-asserted-by":"crossref","unstructured":"Sohal J, Chase A, Mould S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer\u20082001; 32: 155\u201363.","DOI":"10.1002\/gcc.1177"},{"key":"2022061621035889100_B15","doi-asserted-by":"crossref","unstructured":"Lupas A, Van Dyke M, Stock J. Predicting coiled coils from protein sequences. Science\u20081991; 252: 1162\u20134.","DOI":"10.1126\/science.252.5009.1162"},{"key":"2022061621035889100_B16","doi-asserted-by":"crossref","unstructured":"Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood\u20081997; 90: 2535\u201340.","DOI":"10.1182\/blood.V90.7.2535"},{"key":"2022061621035889100_B17","doi-asserted-by":"crossref","unstructured":"Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science\u20081997; 278: 1309\u201312.","DOI":"10.1126\/science.278.5341.1309"},{"key":"2022061621035889100_B18","unstructured":"Griesinger F, Podleschny M, Steffens R, et al. A novel BCR-JAK2 fusion gene is the result of a translocation (9;22)(p24;q11) in a case of CML. Blood\u20082000; 96: 352a."},{"key":"2022061621035889100_B19","unstructured":"Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol\u20081996; 95: 2\u20139."},{"key":"2022061621035889100_B20","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to Imatinib therapy. Blood\u20082003; 102: 3093\u20136.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2022061621035889100_B21","doi-asserted-by":"crossref","unstructured":"Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia\u20082004; 18: 734\u201342.","DOI":"10.1038\/sj.leu.2403313"},{"key":"2022061621035889100_B22","doi-asserted-by":"crossref","unstructured":"Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood\u20082004; 104: 3038\u201345.","DOI":"10.1182\/blood-2004-03-0787"},{"key":"2022061621035889100_B23","unstructured":"Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975\u20132000. Bethesda (MD): National Cancer Institute; 2003."},{"key":"2022061621035889100_B24","doi-asserted-by":"crossref","unstructured":"Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol\u20082002; 118: 1071\u20137.","DOI":"10.1046\/j.1365-2141.2002.03750.x"},{"key":"2022061621035889100_B25","doi-asserted-by":"crossref","unstructured":"Balczon R, Bao L, Zimmer WE. PCM-1, a 228-kD centrosome autoantigen with a distinct cell cycle distribution. J Cell Biol\u20081994; 124: 783\u201393.","DOI":"10.1083\/jcb.124.5.783"},{"key":"2022061621035889100_B26","doi-asserted-by":"crossref","unstructured":"Dammermann A, Merdes A. Assembly of centrosomal proteins and microtubule organization depends on PCM-1. J Cell Biol\u20082002; 159: 255\u201366.","DOI":"10.1083\/jcb.200204023"},{"key":"2022061621035889100_B27","doi-asserted-by":"crossref","unstructured":"Vizmanos JL, Novo FJ, Roman JP, et al. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res\u20082004; 64: 2673\u20136.","DOI":"10.1158\/0008-5472.CAN-04-0144"},{"key":"2022061621035889100_B28","doi-asserted-by":"crossref","unstructured":"Corvi R, Berger N, Balczon R, Romeo G. RET\/PCM-1: a novel fusion gene in papillary thyroid carcinoma. Oncogene\u20082000; 19: 4236\u201342.","DOI":"10.1038\/sj.onc.1203772"},{"key":"2022061621035889100_B29","doi-asserted-by":"crossref","unstructured":"Verma A, Kambhampati S, Parmar S, Platanias LC. Jak family of kinases in cancer. Cancer Metastasis Rev\u20082003; 22: 423\u201334.","DOI":"10.1023\/A:1023805715476"},{"key":"2022061621035889100_B30","doi-asserted-by":"crossref","unstructured":"Xie S, Wang Y, Liu J, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene\u20082001; 20: 6188\u201395.","DOI":"10.1038\/sj.onc.1204834"},{"key":"2022061621035889100_B31","doi-asserted-by":"crossref","unstructured":"Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature\u20081996; 379: 645\u20138.","DOI":"10.1038\/379645a0"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/7\/2662\/2542755\/2662-2667.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/7\/2662\/2542755\/2662-2667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T22:16:02Z","timestamp":1655417762000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/7\/2662\/519660\/The-t-8-9-p22-p24-Is-a-Recurrent-Abnormality-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2005,4,1]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-04-4263","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,1]]}}}